4.83
-0.01 (-0.21%)
| Previous Close | 4.84 |
| Open | 4.80 |
| Volume | 1,715,725 |
| Avg. Volume (3M) | 1,320,760 |
| Market Cap | 514,849,024 |
| Price / Book | 1.58 |
| 52 Weeks Range | |
| Earnings Date | 24 Mar 2025 - 28 Mar 2025 |
| Diluted EPS (TTM) | -1.03 |
| Total Debt/Equity (MRQ) | 8.37% |
| Current Ratio (MRQ) | 21.81 |
| Operating Cash Flow (TTM) | -101.74 M |
| Levered Free Cash Flow (TTM) | -60.81 M |
| Return on Assets (TTM) | -24.83% |
| Return on Equity (TTM) | -42.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Annexon, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -3.5 |
| Average | -1.00 |
|
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.50% |
| % Held by Institutions | 106.10% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Logos Global Management Lp | 30 Sep 2024 | 2,600,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (HC Wainwright & Co., 521.12%) | Buy |
| Median | 23.00 (376.19%) | |
| Low | 16.00 (Needham, 231.26%) | Buy |
| Average | 23.00 (376.19%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 5.50 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 17 Dec 2024 | 30.00 (521.12%) | Buy | 4.88 |
| 15 Nov 2024 | 30.00 (521.12%) | Buy | 6.12 | |
| Needham | 15 Nov 2024 | 16.00 (231.26%) | Buy | 6.12 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |